• VolitionRx flagged a new clinical study milestone with submission of a feline lymphoma manuscript for its Nu.Q Vet blood test.
• Results have already been presented in the submitted paper; publication is still pending.
• The study supports the test’s ability to detect feline lymphoma with clinically useful accuracy, positioning it for broader veterinary adoption.
• Publication is expected to trigger a USD 5 million contractual milestone payment, adding a near-term catalyst for cash inflows.
• Separately, a planned French DETECSEPS program is set to evaluate the Nu.Q NETs assay for earlier sepsis risk identification later in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN68884) on May 27, 2026, and is solely responsible for the information contained therein.